TNFRSF17 and Miyoshi myopathy: Preclinical studies have shown its ability to induce cytolysis of GPRC5D+ MM cells without significant toxicity, even in heavily treated RRMM patients, including those resistant to anti-CD38 or anti-BCMA therapies [75].